Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
This study was conducted in 2 parts. Part A was a randomized, double-blind,
 placebo-controlled, multicenter, sequential dose-escalating evaluation. Part B was a
 randomized, double-blind (operating under in-house blinding procedures), placebo-controlled,
 multicenter, dose-ranging study.
Inclusion Criteria:

 -  Healthy females 16 to 23 years of age

 -  Not pregnant at enrollment and must have agreed to use effective contraception through
 Month 7 of the study

 -  Lifetime history of 0 to 4 male sexual partners (individuals with whom penetrative
 sexual intercourse occurred)

 Exclusion Criteria:

 -  No prior receipt of an Human Papillomavirus (HPV) vaccine

 -  No receipt of inactivated or recombinant vaccines within 14 days prior to enrollment
 or receipt of live vaccines within 21 days prior to enrollment

 -  No prior abnormal Pap test showing squamous intraepithelial lesion (SIL) or biopsy
 showing cervical intraepithelial neoplasia (CIN)

 -  No prior history of genital warts or treatment for genital warts